000			01502 a2200385 4500
005			20250517202139.0
264		0	_c20190116
008			201901s 0 0 eng d
022			_a1476-4598
024	7		_a10.1186/s12943-018-0792-2 _2doi
040			_aNLM _beng _cNLM
100	1		_aMontor, Wagner Ricardo
245	0	0	_aReceptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. _h[electronic resource]
260			_bMolecular cancer _c02 2018
300			_a55 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBiomarkers, Tumor
650	0	4	_aClinical Trials as Topic
650	0	4	_aDrug Discovery
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aHumans
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aMutation
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aProtein Binding
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aReceptor Protein-Tyrosine Kinases _xantagonists & inhibitors
650	0	4	_aSignal Transduction _xdrug effects
700	1		_aSalas, Andrei Ronaldo Oliveira Silva Escartin
700	1		_aMelo, Fabiana Henriques Machado de
773	0		_tMolecular cancer _gvol. 17 _gno. 1 _gp. 55
856	4	0	_uhttps://doi.org/10.1186/s12943-018-0792-2 _zAvailable from publisher's website
999			_c28097834 _d28097834